Solanum incanum extract downregulates aldehyde dehydrogenase 1-mediated stemness and inhibits tumor formation in ovarian cancer cells

Yi Hui Wu, Wen Tai Chiu, Ming Jer Young, Tzu Hao Chang, Yu Fang Huang, Cheng Yang Chou

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Solanum incanum extract (SR-T100), containing the active ingredient solamargine, can induce apoptosis via upregulation of tumor necrosis factor receptor expression and activation of the mitochondrial apoptosis pathway, and has therapeutic effects in patients with actinic keratosis. Here, we evaluate the novel molecular mechanisms underlying SR-T100-regulated stemness and chemoresistance. The concentration of SR-T100 that inhibited 50% cell viability (IC50) was lower in ovarian cancer cells than in nonmalignant cells. Furthermore, the SR-T100 IC50 in chemoresistant cells was similar to the IC50 in chemosensitive cells. Additionally, SR-T100 increased cisplatin and paclitaxel sensitivity in chemoresistant cells. SR-T100 downregulated the expression of stem cell markers, including aldehyde dehydrogenase 1 (ALDH1), Notch1, and FoxM1, and reduced sphere formation in ovarian cancer cells. Using microarray analyses, immunoblotting, luciferase activity, and chromatin immunoprecipitation (ChIP) assays, we showed that SR-T100 suppressed the expression of c/EBPß and COL11A1, and its promoter activity, in resistant cells, but not sensitive cells. SR-T100, paclitaxel, and cisplatin inhibited the growth of A2780CP70 cells in mouse xenografts, as compared to the vehicle control, and the combination of cisplatin and SR-T100 was more effective than either treatment alone. SR-T100 may represent a potential therapeutic adjunct to chemotherapy for ovarian cancer treatment.

Original languageEnglish
Pages (from-to)1011-1019
Number of pages9
JournalJournal of Cancer
Volume6
Issue number10
DOIs
Publication statusPublished - 2015

Fingerprint

Solanum
Ovarian Neoplasms
Down-Regulation
Neoplasms
Inhibitory Concentration 50
aldehyde dehydrogenase 1
SR-T100
Apoptosis
Actinic Keratosis
Tumor Necrosis Factor Receptors
Chromatin Immunoprecipitation
Therapeutic Uses
Microarray Analysis
Luciferases
Immunoblotting
Heterografts
Cisplatin
Cell Survival
Up-Regulation
Stem Cells

Keywords

  • Aldehyde dehydrogenase 1
  • Chemoresistance
  • Ovarian cancer
  • Solanum incanum
  • Stemness

ASJC Scopus subject areas

  • Oncology

Cite this

Solanum incanum extract downregulates aldehyde dehydrogenase 1-mediated stemness and inhibits tumor formation in ovarian cancer cells. / Wu, Yi Hui; Chiu, Wen Tai; Young, Ming Jer; Chang, Tzu Hao; Huang, Yu Fang; Chou, Cheng Yang.

In: Journal of Cancer, Vol. 6, No. 10, 2015, p. 1011-1019.

Research output: Contribution to journalArticle

Wu, Yi Hui ; Chiu, Wen Tai ; Young, Ming Jer ; Chang, Tzu Hao ; Huang, Yu Fang ; Chou, Cheng Yang. / Solanum incanum extract downregulates aldehyde dehydrogenase 1-mediated stemness and inhibits tumor formation in ovarian cancer cells. In: Journal of Cancer. 2015 ; Vol. 6, No. 10. pp. 1011-1019.
@article{717d4803687447758c796ed0dff11efe,
title = "Solanum incanum extract downregulates aldehyde dehydrogenase 1-mediated stemness and inhibits tumor formation in ovarian cancer cells",
abstract = "Solanum incanum extract (SR-T100), containing the active ingredient solamargine, can induce apoptosis via upregulation of tumor necrosis factor receptor expression and activation of the mitochondrial apoptosis pathway, and has therapeutic effects in patients with actinic keratosis. Here, we evaluate the novel molecular mechanisms underlying SR-T100-regulated stemness and chemoresistance. The concentration of SR-T100 that inhibited 50{\%} cell viability (IC50) was lower in ovarian cancer cells than in nonmalignant cells. Furthermore, the SR-T100 IC50 in chemoresistant cells was similar to the IC50 in chemosensitive cells. Additionally, SR-T100 increased cisplatin and paclitaxel sensitivity in chemoresistant cells. SR-T100 downregulated the expression of stem cell markers, including aldehyde dehydrogenase 1 (ALDH1), Notch1, and FoxM1, and reduced sphere formation in ovarian cancer cells. Using microarray analyses, immunoblotting, luciferase activity, and chromatin immunoprecipitation (ChIP) assays, we showed that SR-T100 suppressed the expression of c/EBP{\ss} and COL11A1, and its promoter activity, in resistant cells, but not sensitive cells. SR-T100, paclitaxel, and cisplatin inhibited the growth of A2780CP70 cells in mouse xenografts, as compared to the vehicle control, and the combination of cisplatin and SR-T100 was more effective than either treatment alone. SR-T100 may represent a potential therapeutic adjunct to chemotherapy for ovarian cancer treatment.",
keywords = "Aldehyde dehydrogenase 1, Chemoresistance, Ovarian cancer, Solanum incanum, Stemness",
author = "Wu, {Yi Hui} and Chiu, {Wen Tai} and Young, {Ming Jer} and Chang, {Tzu Hao} and Huang, {Yu Fang} and Chou, {Cheng Yang}",
year = "2015",
doi = "10.7150/jca.12738",
language = "English",
volume = "6",
pages = "1011--1019",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "10",

}

TY - JOUR

T1 - Solanum incanum extract downregulates aldehyde dehydrogenase 1-mediated stemness and inhibits tumor formation in ovarian cancer cells

AU - Wu, Yi Hui

AU - Chiu, Wen Tai

AU - Young, Ming Jer

AU - Chang, Tzu Hao

AU - Huang, Yu Fang

AU - Chou, Cheng Yang

PY - 2015

Y1 - 2015

N2 - Solanum incanum extract (SR-T100), containing the active ingredient solamargine, can induce apoptosis via upregulation of tumor necrosis factor receptor expression and activation of the mitochondrial apoptosis pathway, and has therapeutic effects in patients with actinic keratosis. Here, we evaluate the novel molecular mechanisms underlying SR-T100-regulated stemness and chemoresistance. The concentration of SR-T100 that inhibited 50% cell viability (IC50) was lower in ovarian cancer cells than in nonmalignant cells. Furthermore, the SR-T100 IC50 in chemoresistant cells was similar to the IC50 in chemosensitive cells. Additionally, SR-T100 increased cisplatin and paclitaxel sensitivity in chemoresistant cells. SR-T100 downregulated the expression of stem cell markers, including aldehyde dehydrogenase 1 (ALDH1), Notch1, and FoxM1, and reduced sphere formation in ovarian cancer cells. Using microarray analyses, immunoblotting, luciferase activity, and chromatin immunoprecipitation (ChIP) assays, we showed that SR-T100 suppressed the expression of c/EBPß and COL11A1, and its promoter activity, in resistant cells, but not sensitive cells. SR-T100, paclitaxel, and cisplatin inhibited the growth of A2780CP70 cells in mouse xenografts, as compared to the vehicle control, and the combination of cisplatin and SR-T100 was more effective than either treatment alone. SR-T100 may represent a potential therapeutic adjunct to chemotherapy for ovarian cancer treatment.

AB - Solanum incanum extract (SR-T100), containing the active ingredient solamargine, can induce apoptosis via upregulation of tumor necrosis factor receptor expression and activation of the mitochondrial apoptosis pathway, and has therapeutic effects in patients with actinic keratosis. Here, we evaluate the novel molecular mechanisms underlying SR-T100-regulated stemness and chemoresistance. The concentration of SR-T100 that inhibited 50% cell viability (IC50) was lower in ovarian cancer cells than in nonmalignant cells. Furthermore, the SR-T100 IC50 in chemoresistant cells was similar to the IC50 in chemosensitive cells. Additionally, SR-T100 increased cisplatin and paclitaxel sensitivity in chemoresistant cells. SR-T100 downregulated the expression of stem cell markers, including aldehyde dehydrogenase 1 (ALDH1), Notch1, and FoxM1, and reduced sphere formation in ovarian cancer cells. Using microarray analyses, immunoblotting, luciferase activity, and chromatin immunoprecipitation (ChIP) assays, we showed that SR-T100 suppressed the expression of c/EBPß and COL11A1, and its promoter activity, in resistant cells, but not sensitive cells. SR-T100, paclitaxel, and cisplatin inhibited the growth of A2780CP70 cells in mouse xenografts, as compared to the vehicle control, and the combination of cisplatin and SR-T100 was more effective than either treatment alone. SR-T100 may represent a potential therapeutic adjunct to chemotherapy for ovarian cancer treatment.

KW - Aldehyde dehydrogenase 1

KW - Chemoresistance

KW - Ovarian cancer

KW - Solanum incanum

KW - Stemness

UR - http://www.scopus.com/inward/record.url?scp=84947716780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947716780&partnerID=8YFLogxK

U2 - 10.7150/jca.12738

DO - 10.7150/jca.12738

M3 - Article

VL - 6

SP - 1011

EP - 1019

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 10

ER -